Our take
KIRO Oncology uses two robotic arms, cameras, barcode readers, and scales to prepare hazardous drug doses in syringes, IV bags, cassettes, and elastomeric pumps inside an enclosed, self-cleaning ISO 5 chamber.1,2
It suits hospital oncology pharmacies that want gravimetric checks at every step. Prices are not published.1
Scores by criterion
Pricing transparency, 2.5: Kiro Grifols publishes no prices and sends buyers to a contact form.1
Product maturity, 8.0: The system has a 12-position vial carousel, a bay for up to 8 final containers, a syringe holder for up to 8 syringes, and two peristaltic pumps for diluent filling and reconstitution.1
Deployment evidence, 6.5: Kiro Grifols sells KIRO Oncology alongside KIRO Fill and Gri-fill 4 as part of its inclusiv portfolio, but its site names few hospital sites.2
Company durability, 9.0: Kiro Grifols belongs to Grifols, a listed healthcare group with revenue of 7,524 million euros in 2025.2,3
Ease of integration, 7.5: KIRO Oncology offers a hospital information system interface, multi-device integration, and compatibility with closed system transfer devices.2
Each criterion is defined on our methodology page.
Who uses KIRO Oncology and what it's for
The buyer is a hospital oncology pharmacy that compounds patient-specific hazardous doses and small batches and wants enclosed, self-cleaning automation.1
KIRO Oncology
Self-cleaning and waste disposal run inside the enclosed chamber under negative pressure, with HEPA exhaust filtration and 30% or 100% exhaust options.1
Pricing
Kiro Grifols sells by quote and does not list prices.1
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where KIRO Oncology wins or loses |
|---|---|---|---|---|
| KIRO Oncology | Two-arm hazardous drug compounder with gravimetric checks1 | Not published; quote1 | Part of the inclusiv IV compounding portfolio2 | Two-arm hazardous compounder; quote only; Grifols |
| ARxIUM | RIVA IV robot plus packagers, cabinets, and inventory software4 | Not published; consultation12 | More than 19 million RIVA doses5 | ARxIUM wins on one vendor for IV robots and wider pharmacy automation. KIRO Oncology wins on gravimetric checks and self-cleaning. |
| EQUASHIELD Pro | Automated hazardous drug compounder using closed transfer devices7 | Not published; quote7 | Equashield sells on five continents8 | EQUASHIELD Pro wins on closed transfer protection from start to finish. KIRO Oncology wins on gravimetric checks and self-cleaning. |
| Omnicell | IVX Station robot inside the IV Compounding Service10 | Not published; service model10 | Hospitals, clinics, and care settings9 | Omnicell wins on a managed IV compounding service. KIRO Oncology wins on gravimetric checks and self-cleaning. |
| Loccioni APOTECAchemo | APOTECAchemo IV chemotherapy compounding robot11 | Not published11 | User community across the US, Europe, the Gulf, and Asia11 | Loccioni wins on an established chemo compounding user community. KIRO Oncology wins on gravimetric checks and self-cleaning. |
Limits
No published prices.1
Few named hospital deployments on its site.2
Built for hazardous drugs; non-hazardous batches go to KIRO Fill.2
What customers say
Where it helps
Gravimetric checks and camera identification at every step.1
Where it falls short
Quote-only pricing.1
Company backing
Kiro Grifols is part of Grifols, a listed healthcare group with 7,524 million euros of 2025 revenue, so this page is scoped to its KIRO Oncology robot.2,3
Sources
- Kiro Grifols, KIRO Oncology, accessed November 10, 2026
- Kiro Grifols, Robotic and other compounding devices, accessed November 10, 2026
- Grifols, Grifols reports revenues of EUR 7,524m, up 7% (February 26, 2026), accessed November 10, 2026
- ARxIUM, RIVA robotic IV automation and compounding systems, accessed November 10, 2026
- ARxIUM, News and events hub, accessed November 10, 2026
- ARxIUM, Our headquarters, accessed November 10, 2026
- Equashield, EQUASHIELD Pro automated compounding of hazardous drugs, accessed November 10, 2026
- Nordic Capital, Equashield portfolio company profile, accessed November 10, 2026
- Omnicell, homepage, accessed November 10, 2026
- Omnicell, IV compounding, accessed November 10, 2026
- Loccioni, Apoteca Community, accessed November 10, 2026
- ARxIUM, homepage, accessed November 10, 2026
- Omnicell, Fiscal year and fourth quarter 2025 financial results, accessed November 16, 2026

